NICE ‘no’ for Opdivo/Yervoy lung cancer combo
The combination is not considered to be a cost-effective use of NHS resources in this setting
Read More
Author: Selina McKee
Human trials for world’s first AI-designed immuno-oncology drug
The drug was discovered through an AI-design platform within just eight months of project initiation
Read More
Lilly, Incyte’s Olumiant fails in COVID-19 trial
The drug failed to significantly reduce progression to ventilation or death in patients hospitalised with COVID-19
Read More
Achilles’ US IPO closed with proceeds of $175m
The Cancer Research UK spinout is developing precision T cell therapies to treat multiple cancers
Read More
Novartis bags EU, UK licences for MS therapy Kesimpta
Kesimpta is the first self-administered B-cell therapy for patients with relapsing forms of multiple sclerosis
Read More- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
